StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M)

Form 10-Q / 10-K Consolidated Statements of Earnings & Note 5

Latest, FY2025
602
Period ended Dec 31, 2025
Change on a year earlier
-38.3%
975 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M)Year on yearSource
FY2025Dec 31, 2025602-38.3%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024975+67.5%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023582+84.8%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 2022315+64.1%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021192-22.6%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 2020248-35.6%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 2019385-9.2%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018424+247.5%Form 10-K (filed 2021-02-19) ↗
FY2017Dec 31, 2017122-39.0%Form 10-K (filed 2020-02-21) ↗
FY2016Dec 31, 2016200+300.0%Form 10-K (filed 2019-02-27) ↗
FY2015Dec 31, 201550–Form 10-K (filed 2018-02-16) ↗

Breakdown

What makes up acquired ipr&d and milestones expense — upfront & collaboration charges ($m)

Cite this data

StockData. (2026). AbbVie Acquired IPR&D and Milestones Expense — Upfront & Collaboration Charges ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/iprd_upfront_exp

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.